CLAIMS

- 1. A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and HPMCAS, said dispersion providing a maximum concentration of said drug in a use environment that is higher by a factor of at least 1.5 relative to a control composition comprising an equivalent quantity of undispersed drug.
- A composition as decribed in claim 1, wherein said drug has a dose to aqueous solubility ratio greater than 100.
- A composition as defined in claim 1, wherein said drug is crystalline 3. when undispersed.
- 4. A composition as defined in claim 1, wherein said drug is amorphous when undispersed.
- A composition as defined in claim 1, wherein said use environment is 5. the gastrointestinal tract.
- A composition as defined in claim 1, wherein said use environment is MFD.
- 7. A composition of matter comprising a spray-dried solid dispersion, which dispersion comprises a sparingly soluble drug and HPMCAS, said dispersion exhibiting a maximum supersaturated concentration in MFD which is higher by a factor of at least 1.5 relative to the equilibrium concentration exhibited by a control composition comprising an equivalent quantity of undispersed drug.
- 8. A composition as decribed in claim 7, wherein said drug has a dose to aqueous solubility ratio greater than 100.
- 9. A composition as defined in claim 7, wherein said drug is crystalline when undispersed.
 - 10. A composition as defined in claim 7, wherein said drug is amorphous when undispersed.
 - 11. A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and HPMCAS, said dispersion effecting, in vivo, a maximal observed blood drug concentration (C_{max}) that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug.

25

30

20

5

10

15

10

15

20

25

- 12. A composition as defined in claim 11, wherein said drug is crystalline when undispersed.
- A composition as defined in claim 11, wherein said drug is amorphous when undispersed.
- 5 14. A composition as decribed in claim 11, wherein said drug has a dose to aqueous solubility ratio greater than 100.
 - 15. A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and HPMCAS, said dispersion effecting, *in vivo*, an AUC that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug.
 - 16. A composition as defined in claim 15, wherein said drug is crystalline when undispersed.
 - 17. A composition as defined in claim 15, wherein said drug is amorphous when undispersed.
 - 18. A composition as decribed in claim 15, wherein said drug has a dose to aqueous solubility ratio greater than 100.
 - 19. A process for making a spray dried solid dispersion comprising
 - A. forming a solution comprising (i) HPMCAS, (ii) a sparingly water-soluble drug, and (iii) a solvent in which both (i) and (ii) are soluble; and
 - B. spray drying said solution, thereby forming spray dried particles having an average diameter less than 100 μm .
 - 20. A process as defined in claim 19, wherein the concentration of drug in said solvent is less than 20g/100g of solvent.
 - 21. A process as defined in claim 19, wherein the spray drying is conducted under conditions whereby said droplets solidify in less than 20 seconds.
 - 22. A composition as defined in claim 1, wherein the concentration of drug in MFD falls to no less than 25% of the maximum supersaturated concentration during the 15 minutes following the time at which the maximum supersaturated concentration is reached.
- 30 23. A composition as defined in claim 1, wherein said dispersion is in the form of particles less than 100 μm in diameter.

- 24. A composition as defined in claim 7, wherein said dispersion is in the form of particles less than 100 μm in diameter.
- 25. A composition as defined in claim 11, wherein said dispersion is in the form of particles less than 100 μ m in diameter.
- 26. A composition as defined in claim 15, wherein said dispersion is in the form of particles less than 100 μm in diameter.
- 27. A composition as defined in claim 1, wherein the drug to HPMCAS weight ratio is from 1/0.2 to 1/100.
- 28. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is a glycogen phosphorylase inhibitor.
- 29. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is

or a pharmaceutically acceptable salt thereof.

30. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is

15

5

10

10

or a pharmaceutically acceptable salt thereof.

- 31. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is a 5-lipoxygenase inhibitor.
- 5 32. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is

or a pharmaceutically acceptable salt thereof.

- 33. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is a CRH inhibitor.
- 34. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is

15

or a pharmaceutically acceptable salt thereof.

35. • A composition as defined in claims 1, 7, 11, or 15, wherein said compound is

5

or a pharmaceutically acceptable salt thereof.

- 36. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is an antipsychotic.
- 37. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is ziprasidone.
- 38. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is selected from griseofulvin, nifedipine, and phenytoin.